Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study

“…Despite advances in prevention and associated improvements in outcomes, patients with systemic autoimmune rheumatic disease remain at increased risk of SARS-CoV-2 infection, severe COVID-19 outcomes, and prolonged symptom duration, especially those who are receiving B-cell-depleting therapy or who have comorbid conditions, such as interstitial lung disease. 16 , 19 , 21 Although vaccination reduces risk of severe outcomes, patients with rheumatoid arthritis have increased risk of SARS-CoV-2 infection and severe outcomes compared with the general population. 26 Thus, even with improving COVID-19 outcomes, some patients with systemic autoimmune rheumatic disease remain vulnerable to poor COVID-19 outcomes.…”

“…We also identified individual components of the Charlson Comorbidity Index as well as interstitial lung disease, which has been previously associated with worse COVID-19 outcomes. 21 The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation without the race multiplier. We categorised eGFR as less than 30 mL/min/1·73 m 2 (severely decreased kidney function), 30 mL/min/1·73 m 2 to less than 60 mL/min/1·73 m 2 (moderately decreased kidney function), or 60 mL/min/1·73 m 2 or greater (normal kidney function), because this affects nirmatrelvir–ritonavir dosing and eligibility.…”

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study

“…Despite advances in prevention and associated improvements in outcomes, patients with SARDs remain at elevated risk for SARS-CoV-2 infection, severe outcomes, and prolonged symptom duration, especially those who are on B cell depleting therapy or have comorbid conditions like interstitial lung disease(19, 24, 26). Although vaccination reduces risk for severe outcomes, RA patients have elevated risks for SARS-CoV-2 infection and severe outcomes compared to the general population(32).…”

“…We calculated the Charlson Comorbidity Index (CCI)(25) from ICD-10 codes in the one year prior to index date. We also identified individual components of the CCI as well as interstitial lung disease, which has been previously associated with worse COVID-19 outcomes(26). The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation without the race multiplier(27).…”

Rheuma nach COVID-19-Infektion oder Impfung

“…Seit Beginn der Pandemie bestand die Sorge, dass Patienten mit Autoimmunerkrankung in Bezug auf COVID verstärkt gefährdet seien und ein höheres Risiko für schwerwiegende Komplikationen hätten. Die bisherige Erfahrung hat das aber nicht wirklich bestätigt [32][33][34].…”